Velcade (Bortezomib) Receives 2 New FDA Indications: For Retreatment of Patients with Multiple Myeloma and for First-Line Treatment of Patients with Mantle-Cell Lymphoma
about
Mechanism-Based Strategies for the Management of Autoimmunity and Immune Dysregulation in Primary ImmunodeficienciesThe preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma.Targeting the 26S Proteasome To Protect Against Proteotoxic Diseases.Infliction of proteotoxic stresses by impairment of the unfolded protein response or proteasomal inhibition as a therapeutic strategy for mast cell leukemia.Epstein–Barr Virus-Induced Metabolic Rearrangements in Human B-Cell Lymphomas.Primary effusion lymphoma: current perspectives.
P2860
Velcade (Bortezomib) Receives 2 New FDA Indications: For Retreatment of Patients with Multiple Myeloma and for First-Line Treatment of Patients with Mantle-Cell Lymphoma
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Velcade (Bortezomib) Receives ...... ents with Mantle-Cell Lymphoma
@ast
Velcade (Bortezomib) Receives ...... ents with Mantle-Cell Lymphoma
@en
type
label
Velcade (Bortezomib) Receives ...... ents with Mantle-Cell Lymphoma
@ast
Velcade (Bortezomib) Receives ...... ents with Mantle-Cell Lymphoma
@en
prefLabel
Velcade (Bortezomib) Receives ...... ents with Mantle-Cell Lymphoma
@ast
Velcade (Bortezomib) Receives ...... ents with Mantle-Cell Lymphoma
@en
P2860
P1476
Velcade (Bortezomib) Receives ...... ents with Mantle-Cell Lymphoma
@en
P2093
Lisa Raedler
P2860
P304
P433
Spec Feature
P577
2015-03-01T00:00:00Z